|1.||Zuccarello, Mario: 1 article (02/2003)|
|2.||Rapoport, Robert M: 1 article (02/2003)|
|3.||Sherman, Jonathan D: 1 article (02/2003)|
|4.||Fandino, Javier: 1 article (02/2003)|
|5.||Bauerová, K: 1 article (01/2003)|
|6.||Kettmann, V: 1 article (01/2003)|
|7.||Doherty, A M: 1 article (01/2003)|
|8.||Drímal, J: 1 article (01/2003)|
|9.||Stefek, M: 1 article (01/2003)|
|10.||Knezl, V: 1 article (01/2003)|
|1.||Ganglion Cysts (Ganglion)
11/01/1995 - "Here we have used the ETA receptor-selective antagonist, BQ-123, the ETB receptor-selective antagonist, BQ-788 and the ETA/ETB receptor non-selective antagonist, PD 145065, to study the role of these receptors in mediating the haemodynamic changes induced by an infusion of ET-1 to the anesthetized ganglion-blocked rat. "
01/01/1995 - "Here we have used the selective ETA receptor antagonist BQ-123, the selective ETB receptor antagonist BQ-788 and the nonselective ETA/ETB receptor antagonist PD 145065 to study the role of these receptors in mediating the hemodynamic changes induced by an infusion of ET-1 to the anesthetised, ganglion-blocked rat. "
02/18/1997 - "Pretreatment with PD 145065 (a nonselective endothelin receptor blocker; 50 micrograms.kg-1.min-1) completely blocked this increase in pulmonary vascular resistance and blocked the increase in pulmonary vascular resistance in response to acute alveolar hypoxia after CPB (96.3 +/- 88.5% versus -9.7 +/- 16.4%; P < .05). "
07/01/1997 - "Perfusate hypoxia caused endothelium-dependent contraction in the arteries of all four groups that could be attenuated by NG-monomethyl-L-arginine (L-NMMA) or L-NMMA plus D-arginine, but not by L-NMMA plus L-arginine or endothelin receptor A and B antagonist PD 145065. "
|3.||Myocardial Ischemia (Ischemic Heart Diseases)
|3.||Endothelin Receptors (Endothelin Receptor)
|5.||omega-N-Methylarginine (NG Monomethyl L Arginine)
|6.||Nitric Oxide Synthase (NO Synthase)
|7.||Cocaine (Cocaine HCl)